Evidence map›Paper›PMID 41743370›Full record

ArticleClinical and translational radiation oncology2026

Motion-based tissue

Katrin S Pachler, Iris Lauwers, Nicole S Verkaik, Marta Rovituso, Hetty Mast, Brend P Jonker, Bernd Kremer, Sjors A Koppes, Thierry P P van den Bosch, Gerda M Verduijn and 4 more

Abstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Katrin S PachlerDepartment of Molecular Genetics, Erasmus MC, P.O. Box 2040, 3000 CA Rotterdam, Netherlands (the).
Iris LauwersDepartment of Radiotherapy, Erasmus MC Cancer Institute, P.O. Box 2040, 3000 CA Rotterdam, Netherlands (the).
Nicole S VerkaikDepartment of Molecular Genetics, Erasmus MC, P.O. Box 2040, 3000 CA Rotterdam, Netherlands (the).
Marta RovitusoHolland Proton Therapy Centre (HPTC), Huismansingel 4, 2629 JH Delft, Netherlands (the).
Hetty MastDepartment of Oral and Maxillofacial Surgery, Erasmus MC Cancer Institute, P.O. Box 2040, 3000 CA Rotterdam, Netherlands (the).
Brend P JonkerDepartment of Oral and Maxillofacial Surgery, Erasmus MC Cancer Institute, P.O. Box 2040, 3000 CA Rotterdam, Netherlands (the).
Bernd KremerDepartment of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, P.O. Box 2040, 3000 CA Rotterdam, Netherlands (the).
Sjors A KoppesDepartment of Pathology, Erasmus MC, P.O. Box 2040, 3000 CA Rotterdam, Netherlands (the).
Thierry P P van den BoschDepartment of Pathology, Erasmus MC, P.O. Box 2040, 3000 CA Rotterdam, Netherlands (the).
Gerda M VerduijnDepartment of Radiotherapy, Erasmus MC Cancer Institute, P.O. Box 2040, 3000 CA Rotterdam, Netherlands (the).
Steven PetitDepartment of Radiotherapy, Erasmus MC Cancer Institute, P.O. Box 2040, 3000 CA Rotterdam, Netherlands (the).
Brita S SørensenDepartment of Radiotherapy, Erasmus MC Cancer Institute, P.O. Box 2040, 3000 CA Rotterdam, Netherlands (the).
Dik C van GentDepartment of Molecular Genetics, Erasmus MC, P.O. Box 2040, 3000 CA Rotterdam, Netherlands (the).
Marta E CapalaDepartment of Radiotherapy, Erasmus MC Cancer Institute, P.O. Box 2040, 3000 CA Rotterdam, Netherlands (the).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: Proton radiotherapy is applied for various tumor sites, offering better dose distribution resulting in decreased excess radiation of healthy tissue. Furthermore, the biological effects of proton irradiation may be different from X-ray irradiation, depending on tumor characteristics. This is particularly relevant for head and neck squamous cell carcinoma (HNSCC), which displays high biological heterogeneity. However, this heterogeneous response to various radiation modalities is currently not included in clinical decision making due to lack of response prediction models. Materials and methods: Nine oral cavity tumor specimens were obtained after surgical resection, cut into thin slices, irradiated with both X-ray and protons, and cultured Results: Most tumors (five out of nine) showed similar response to proton and X-ray irradiation. However, in three tumors a significantly larger decrease in viability was measured upon proton irradiation. One of those tumors was homologous recombination deficient (HRD). The other two proton-sensitive tumors showed low numbers of infiltrating immune cells, including tumor infiltrating lymphocytes, while the most X-ray sensitive tumor had a particularly high immune cell infiltration. Conclusion: The

Indexed as

Ex vivo assayHNSCCHomologous recombination deficiency (HRD)RadiotherapyResponse predictionTumor infiltrating lymphocytes

Identifiers

PMID41743370
PMCPMC12930084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.